uploads/2018/07/Januvia.png

How Is Merck’s Diabetes and Women’s Health Business Positioned?

By

Updated

Diabetes segment revenue trends

In the second quarter of 2018, Merck’s (MRK) Januvia and Janumet generated revenues of $949 million and $585.0 million, respectively. In Q2 2018, Januvia revenues remained flat compared to Q2 2017 while Janumet revenues witnessed ~4% YoY growth. In the second quarter of 2018, both Januvia and Janumet witnessed ~8% sequential growth.

In Q2 2018, in US and international markets, Januvia generated revenues of $503.0 million and $446.0 million, respectively, which reflected a ~7% decline and 10% growth on a YoY basis.

Article continues below advertisement

In Q2 2018, in the US and international markets, Janumet generated revenues of $209.0 million and $377.0 million, respectively, reflecting a ~16% decline and a ~20% increase on a YoY basis. In the first half of 2018, Januvia and Janumet generated revenues of $1.8 billion and $1.1 billion, respectively, which is ~2% and 7% YoY growth.

Merck’s anti-diabetes drugs peers include Eli Lilly’s (LLY) Trajenta, Novartis’s (NVS) Galvus, and AstraZeneca’s (AZN) Onglyza. Notably, Trajenta and Galvus generated revenues of $141.7 million and $332.0 million, respectively, in the second quarter of 2018.

Women’s health revenue trends

In the second quarter of 2018, Merck’s Implanon/Nexplanon generated revenues of $174.0 million, reflecting a ~2% YoY decline. Implanon/Nexplanon’s revenues remained flat sequentially in the second quarter of 2018.

In Q2 2018, in the US market and international markets, Merck’s Implanon/Nexplanon generated revenues of $114.0 million and $60.0 million, respectively, reflecting a ~9% decline and 14% growth on a YoY basis. In the first half of 2018, Implanon/Nexplanon generated revenues of $348.0 million. Implanon/Nexplanon revenues remained flat compared to the same period the prior year.

In Q2 2018, NuvaRing reported revenues of $236.0 million compared to $119.0 million in Q2 2017, reflecting ~19% YoY growth and a ~9% YoY decline. In the second quarter of 2018, in the US and international markets, NuvaRing generated revenues of $187.0 million and $49.0 million, respectively, reflecting ~22% and ~4% YoY increases.

In the first half of 2018, NuvaRing generated revenues of $452.0 million compared to $259.0 million in the first half of 2017, reflecting ~26% YoY growth.

Advertisement

More From Market Realist